



# Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells


Ritu Shrestha, Kim R. Bridle, Lu Cao, Darrell H. G. Crawford and Aparna Jayachandran




**Figure S1.** Silencing of CD73 in human HCC derived spheres. Transfection of Hep3B and PLC/PRF/5 cells with two specific CD73 siRNA effectively knockdown CD73 expression as revealed by (A) qRT-PCR and (B) western blot analysis. GAPDH was used as loading control. ( $n = 3$ ,  $** p < 0.01$ ,  $*** p < 0.005$ ,  $**** p < 0.001$ , ns: not significant).




**Figure S2.** Hep3B derived spheres treatment with Sorafenib. Treatment of Hep3B derived spheres with Sorafenib revealed downregulation of (A) stemness markers and (B) immune checkpoints by qRT-PCR analysis. ( $n = 3$ ,  $* p < 0.05$ ,  $** p < 0.01$ , ns: not significant).




**Figure S3.** PLC/PRF/5 derived spheres treatment with Sorafenib. Treatment of PLC/PRF/5 derived spheres with Sorafenib revealed downregulation of (A) stemness markers *CD44* and *BMI* and upregulation of *KLF-4* and (B) upregulation of immune checkpoints by qRT-PCR analysis. ( $n = 3$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ , ns: not significant).



**Figure S4.** Hep3B derived spheres treatment with SB431542. Treatment of Hep3B derived spheres with SB431542 revealed downregulation of (A) stemness markers and (B) immune checkpoints by qRT-PCR analysis. ( $n = 3$ , \*  $p < 0.05$ , ns: not significant).




**Figure S5.** PLC/PRF/5 derived spheres treatment with SB431542. Treatment of PLC/PRF/5 derived spheres with SB431542 revealed downregulation of (A) stemness markers *CD44* and *BMI* and upregulation of *KLF-4* and (B) upregulation of immune checkpoints by qRT-PCR analysis. ( $n = 3$ , \*  $p < 0.05$ , ns: not significant).




**Figure S6.** Silencing of PD-L1 and CD73 in Hep3B derived spheres. Transfection of Hep3B cells with PD-L1 or CD73 siRNA decreased the expression of stemness markers as revealed by qRT-PCR analysis. ( $n = 3$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.005$ , ns: not significant).

### PLC/PRF/5 Spheres




**Figure S7.** Silencing of PD-L1 and CD73 in PLC/PRF/5 derived spheres. Transfection of PLC/PRF/5 cells with PD-L1 or CD73 siRNA decreased the expression of stemness markers as revealed by qRT-PCR analysis. ( $n = 3$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.005$ , ns: not significant).




Detail information about Figure 2.

**Original blots for Figure 4**




**Detail information about Figure 4.**

**Original blots for Figure 5B**




**Detail information about Figure 5.**

**Original blots for Figure 7D**



Detail information about Figure 7.

**Original blots for Supplementary Figure S1**



Detail information about Figure S1.